Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.35 |
| ▸ | HTR3B | O95264 | 7/20 | 0.35 |
| ▸ | HTR3A | P46098 | 7/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.35 |
| ▸ | SORD | Q00796 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500066 | 0.92 | JAK3 (0.41) | JAK3PARP1ALDH1A1HRH4CYP1A2 | |
| SCHEMBL4524341 | 0.89 | HTR3E (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL942469 | 0.87 | PIK3CB (0.51) | JAK3PIK3CBPIK3CAHTT | |
| SCHEMBL6066498 | 0.78 | ROCK2 (0.38) | JAK3CYP3A4HTTTHPO | |
| SCHEMBL2483773 | 0.73 | JAK3 (0.33) | JAK3ADORA1 | |
| SCHEMBL31609349 | 0.68 | KDM4E (0.46) | ALDH1A1KDM4EMAPK1HTT | |
| SCHEMBL10526565 | 0.68 | CD38 (0.45) | ALDH1A1KDM4ECYP1A2CYP3A4MAPK1 | |
| SCHEMBL5709843 | 0.68 | KDM4E (0.39) | ALDH1A1KDM4ECYP1A2CYP3A4HTT | |
| SCHEMBL103924 | 0.68 | DYRK1A (0.30) | ADORA1 | |
| SCHEMBL16417018 | 0.67 | HTR3A (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171787-A1 | APTAMERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR PREVENTING OR TREATING BCMA-ASSOCIATED DISEASES OR CONDITIONS | Aptapeutics Limited (CN) | 2025-05-29 | — | — | US | claimed |
| EP-3665304-B1 | METHOD FOR SCREENING SPLICING VARIANTS OR EVENTS | AGENCY SCIENCE TECH & RES (SG) | 2026-05-20 | — | — | EP | disclosed |
| US-20260125680-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION | MASSACHUSETTS GEN HOSPITAL (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731186-A2 | METHODS AND COMPOSITIONS FOR TREATING EPITHELIAL DISEASES | The Regents of the University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4729130-A2 | LIPOSOMAL PARTICLES, METHODS OF MAKING SAME AND USES THEREOF | Northwestern University (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4728075-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOE | Leal Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CARIS SCIENCE, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| US-20260097120-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | PHIO PHARMACEUTICALS CORP. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260091053-A1 | TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS | EMPIRICO INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3974436-A1 | CROSSLINKED NUCLEIC ACID GUNA METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2022-03-30 | — | — | EP | disclosed |
| US-11279934-B2 | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN | PHIO PHARMACEUTICALS CORP. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220073919-A1 | THERAPEUTIC OLIGONUCLEOTIDES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-10 | — | — | US | disclosed |
| EP-3962936-A1 | TREATMENT AND PREVENTION OF METABOLIC DISEASES | Singapore Health Services Pte. Ltd. (SG) | 2022-03-09 | — | — | EP | disclosed |
| EP-2521785-B1 | INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A PANCREATIC DEVELOPMENTAL GENE FOR USE IN A TREATMENT OF PANCREATIC DEVELOPMENTAL GENE RELATED DISEASES | CURNA INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220064732-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | BPGBIO, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2022043531-A1 | 7'-SUBSTITUTED 2'-O-4'-C-ETHYLENE-BRIDGED NUCLEIC ACID (ENA) MONOMERS AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-03 | — | — | WO | disclosed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220033819-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIAC DISEASES | JAAN BIOTHERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11230711-B2 | Inhibition of LET7I as a means to enhance the protective effect of progesterone against stroke | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091053-A1 | TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS | TSLP, UPF1, RNGTT | JAK3 2729/4885PIK3CB 3211/4885HTR3E 2381/4885 |
| US-20260125680-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION | PDCD1LG2, CD274, PDCD1 | JAK3 782/4885PIK3CB 3589/4885HTR3E 4294/4885 |
| US-20260097120-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | CD274, PDCD1LG2, ICOS | JAK3 724/4885PIK3CB 4171/4885HTR3E 1821/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | JAK3 4545/4885PIK3CB 1363/4885HTR3E 3177/4885 |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CD63, FLT4, NCL | JAK3 1229/4885PIK3CB 1967/4885HTR3E 2446/4885 |
| US-20220064732-A1 | METHODS FOR TREATING PARKINSON'S DISEASE | SNCA, GBA3, LRRK2 | JAK3 1914/4885PIK3CB 3448/4885HTR3E 560/4885 |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | JAK3 85/4885PIK3CB 1131/4885HTR3E 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.